Skip to main content

Decision XXVI/5 : Global laboratory and analytical-use exemption

Recalling decisions VII/11 and XXI/6, in which the Meeting of the Parties requested all parties to urge their national standards-setting organizations to identify and review their standards for laboratory and analytical procedures that mandate the use of Montreal Protocol controlled substances with a view to adopting, where possible, laboratory and analytical products and processes that do not use controlled substances,

Recalling also decisions VII/11, XI/15, XVIII/15 and XIX/18, by which the Meeting of the Parties eliminated specific uses from the global exemption for laboratory and analytical uses,

  1. To extend the global laboratory and analytical-use exemption until 31 December 2021, under the conditions set out in annex II to the report of the Sixth Meeting of the Parties and decisions XV/8, XVI/16 and XVIII/15, for the controlled substances under the Montreal Protocol in all annexes and groups except Annex C, group 1;
  2. To request the Technology and Economic Assessment Panel to report no later than 2018 on the development and availability of laboratory and analytical procedures that can be performed without using controlled substances under the Montreal Protocol;
  3. To encourage parties to continue to investigate domestically the possibility of replacing ozone-depleting substances in laboratory and analytical uses and to share the resulting information;